Predicted structures of agonist and antagonist bound complexes of adenosine A 3 receptor

Proteins: Structure, Function and Bioinformatics

Volumn 79, Issue 6, 2011, Pages 1878-1897

  Kim, Soo Kyung ^a   Riley, Lindsay ^b   Abrol, Ravinder ^a   Jacobson, Kenneth A ^c   Goddard, William A ^a  

^a California Institute of Technology   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Adenosine receptor; Agonists; Antagonist; Docking; GPCR; Membrane protein predicted structure

Indexed keywords

ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR AGONIST; ADENOSINE A3 RECEPTOR ANTAGONIST; G PROTEIN COUPLED RECEPTOR;

ARTICLE; CELL PROTECTION; COMPARATIVE STUDY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; MOLECULAR DOCKING; MONTE CARLO METHOD; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN STABILITY; PROTEIN STRUCTURE; STRUCTURE ACTIVITY RELATION;

ADENOSINE A3 RECEPTOR AGONISTS; ADENOSINE A3 RECEPTOR ANTAGONISTS; AMINO ACID SEQUENCE; BINDING SITES; COMPUTER SIMULATION; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MONTE CARLO METHOD; PROTEIN BINDING; RECEPTOR, ADENOSINE A3; SEQUENCE ALIGNMENT;

EID: 79955722962     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.23012     Document Type: Article

References (48)

1. Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 2006; 5: 247-264.
2. Jacobson KA, Costanzi S, Kim S-K, Rho E, Joshi BV, Tchilibon S, Duong HT, Gao Z-G. Nucleosides, Action of nucleosides and nucleotides at 7 transmembrane-spanning receptors. Nucleosides Nucleotides Nucleic Acids 2006; 25: 1425-1436.
3. Vu CB, Shields P, Peng B, Kumaravel G, Jin X, Phadke D, Wang J, Engber T, Ayyub E, Petter RC. Triamino derivatives of triazolotriazine and triazolopyrimidine as adenosine A2A receptor antagonists. Bioorg Med Chem Lett 2004; 14: 4835-4838.
4. Tracey WR, Magee WP, Oleynek JJ, Hill RJ, Smith AH, Flynn DM, Knight DR. Novel N6-substituted adenosine 5-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury. Am J Physiol Heart Circ Physiol 2003; 285: H2780-H2787.
5. Shneyvais V, Mamedova L, Zinman T, Jacobson KA, Shainberg A. Activation of A3 adenosine receptor protects against doxorubicin-induced cardiotoxicity. J Mol Cell Cardiol 2001; 33: 1249-1261.
6. Yang H, Avila MY, Peterson-Yantorno K, Coca-Prados M, Stone RA, Jacobson KA, Civan MM. The cross-species A3 adenosine-receptor antagonist MRS1292 inhibits adenosine-triggered human nonpigmented ciliary epithelial cell fluid release and reduces mouse intraocular pressure. Current Eye Res 2005; 30: 747-754.
7. Goddard III WA, Kim SK, Li Y, Trzaskowski B, Griffith AR, Abrol R. Predicted 3D structures for adenosine receptors bound to ligands: comparison to the crystal structure. J Struct Biol 2010; 170: 10-20.
8. Warne T, Serrano-Vega MJ, Baker JG, Moukhametzianov R, Edwards PC, Henderson R, Leslie AGW, Tate CG, Schertler GFX. Structure of a β1-adrenergic G-protein coupled receptor. Nature 2008; 454: 486-491.
9. Jaakola VP, Griffith MT, Hanson MA, Cherezov V, Chien EY, Lane JR, Ijzerman AP, Stevens RC. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Sci 2008; 322: 1211-1277.
10. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SGF, Thian FS, Kobilka TS, Choi H-J, Kuhn P, Weis WI, Kobilka BK, Stevens RC. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Sci 2007; 318: 1258-1265.
11. Vaidehi N, Floriano WB, Trabanino R, Hall SE, Freddolino P, Choi EJ, Goddard WA, III. Structure and function of GPCRs. Proc Natl Acad Sci USA 2002; 99: 12622-12627.
12. Floriano WB, Vaidehi N, Zamanakos G, Goddard IIIWA. HierVLS hierarchical docking protocol for virtual ligand screening of large-molecule databases. J Med Chem 2004; 47: 56-71.
13. Cho AE, Wendel JA, Vaidehi N, Kekenes-Huskey PM, Floriano WB, Maiti PK, Goddard WA, III The MPSim-dock hierarchical docking algorithm: application to the eight trypsin inhibitor co-crystals. J Comp Chem 2005; 26: 48-71.
14. Kalani Y, Vaidehi N, Hall SE, Floriano WB, Trabanino RJ, Freddolino PL, Kam V, Goddard WA, III. Three-dimensional structure of the human D2 dopamine receptor and the binding site and binding affinities for agonists and antagonists. Proc Natl Acad Sci USA 2004; 101: 3815-3820.
15. Freddolino PL, Kalani MY, Vaidehi N, Floriano WB, Trabanino RJ, Freddolino PL, Kam V, Goddard WA, III. Structure and function prediction for human b2- adrenergic receptor. Proc Natl Acad Sci USA 2004; 101: 2736-2741.
16. Spijker P, Vaidehi N, Freddolino PL, Hilbers PA, Goddard WA, III. Dynamic behavior of fully solvated b2-adrenergic receptor, embedded in the membrane with bound agonist or antagonist. Proc Natl Acad Sci USA 2006; 103: 4882-4887.
17. Peng JY, Vaidehi N, Hall SE, Goddard WA, III. The predicted 3D structures of the human M1 muscarinic acetylcholine receptor with agonist or antagonist bound. Chem Med Chem 2006; 1: 878-890.
18. Vaidehi N, Schlyer S, Trabanino RJ, Floriano WB, Abrol R, Sharma S, Kochanny M, Koovakat S, Dunning L, Liang M, Fox JM, de Mendonca FL, Pease JE, Goddard WA, III, Horuk R. Predictions of CCR1 chemokine receptor structure and BX 471 antagonist binding followed by experimental validation. J Biol Chem 2006; 281: 27613-27620.
19. Heo J, Han S-K, Vaidehi N, Wendel J, Kekenes-Huskey P, Goddard WA, III. Prediction of the 3D structure of FMRF-amide neutopeptides bound to the mouse MrgC11 GPCR and experimental validation. Chem Bio Chem 2007; 8: 1527-1539.
20. Heo J, Vaidehi N, Wendel J, Goddard WA, III. Prediction of the 3-D structure of rat MrgA G protein-coupled receptor and identification of its binding site. J Mol Graph Model 2007; 26: 800-812.
21. Li Y, Zhu F, Vaidehi N, Goddard III WA, Sheinerman F, Reiling S, Morize I, Mu L, Harris K, Ardati A, Laoui A. Prediction of the 3D structure and dynamics of human DP G-protein coupled receptor bound to an agonist and an antagonist. J Am Chem Soc 2007; 129: 10720-10731.
22. Bray JK, Goddard WA, III. The structure of human serotonin 2c G-protein-coupled receptor bound to agonists and antagonists. J Mol Graph Model 2008; 27: 66-81.
23. Katoh K, Kuma K, Toh H, Miyata T. MAFFT version 5: improvement in accuracy of multiple sequence alignment. Nucleic Acid Res 2005; 33: 511-518.
24. Wimley WC, Creamer TP, White SH. Solvation energies of amino acid side chains and backbone in a family of host-guest pentapeptides. Biochem 1996; 35: 5109-5124.
25. Hessa T M-BN, Bernsel A, Kim H, Sato Y, Lerch-Bader M, Nilsson I, White SH, von Heijne G. Molecular code for transmembrane-helix recognition by the Sec61 translocon. Nature 2007; 450: 1026-1030.
26. Raghava GPS. APSSP2: a combination method for protein secondary structure prediction based on neural network and example based learning. CASP5 2002: A-132.
27. Pollastri G, McLysaght A. Porter: a new, accurate server for protein secondary structure prediction. Bioinformatics 2005; 21: 1719-1720.
28. Kam VWT, Goddard WA, III. Flat-bottom strategy for improved accuracy in protein side-chain placements. J Chem Theo Comp 2008; 4: 2160-2169.
29. Okada T, Sugihara M, Bondar AN, Elstner M, Entel P, Buss V. The retinal conformation and its environment in rhodopsin in light of a new 2.2 Å crystal structure. J Mol Biol 2004; 342: 571-583.
30. Park JH, Scheerer P, Hofmann KP, Choe HW, Ernst OP. Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature 2008; 454: 183-187.
31. Mayo SL, Olafson BD, Goddard IIIWA. DREIDING-a generic force field for molecular simulations. J Phys Chem 1990; 94: 8897-8909.
32. Kim S-K, Li Y, Park C, Abrol R, Goddard WA, III. Prediction of the 3D structure for the rat urotensin II receptor and comparison of the antagonist binding sites and binding selectivity between human and rat from atomistic simulations. Chem Med Chem 2010; 5: 1594-1608.
33. Bhandarkar M, Brunner R, Chipot C, Dalke A, Dixit S, Grayson P, Gullingsrud J, Gursoy A, Hardy D, Hénin J, Humphrey W, Hurwitz D, Krawetz N, Kumar S, Nelson M, Phillips J, Schinozaki A, Zheng G, Zhu F. NAMD User's Guide. Theoretical Biophysics Group, University of Illinois at Urbana-Champaign and Beckman Institute, Urbana, 2008; Version 2.6.
34. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, Chipot C, Skeel RD, Kale L, K. S. Scalable molecular dynamics with NAMD. J Comput Chem 2005; 26: 1781-1802.
35. MacKerell AD, Bashford D, Bellott M, Dunbrack RL, Evanseck JD, Field MJ, Fischer S, Gao J, Guo H, Ha S, Joseph-McCarthy D, Kuchnir L, Kuczera K, Lau FTK, Mattos C, Michnick S, Ngo T, Nguyen DT, Prodhom B, Reiher WE, Roux B, Schlenkrich M, Smith JC, Stote R, Straub J, Watanabe M, Wiorkiewicz-Kuczera J, Yin D, Karplus M. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B 1998; 102: 3586-3616.
36. Feller SE, Yin D, Pastor RW, MacKerell ADJr. Molecular dynamics simulation of unsaturated lipids at low hydration: parametrization and comparison with diffraction studies. Biophys J 1997; 73: 2269-2279.
37. Melman A, Wang B, Joshi BV, Gao ZG, Castro S, Heller CL, Kim S-K, Jeong LS, Jacobson KA. Selective A(3) adenosine receptor antagonists derived from nucleosides containing a bicyclo[3.1.0]hexane ring system. Bioorg Med Chem 2008; 16: 8546-8556.
38. Tosh DK, Chinn M, Ivanov AA, Klutz AM, Gao ZG, Jacobson KA. Functionalized congeners of A3 adenosine receptor-selective nucleosides containing a bicyclo[3.1.0]hexane ring system. J Med Chem 2009; 52: 7580-7592.
39. Ruprecht JJ, Mielke T, Vogel R, Villa C, Schertler GFX. Electron crystallography reveals the sturcture of metarhodopsin I. EMBO J 2004; 23: 3609-3620.
40. Pellissier LP, Sallander J, Campillo M, Gaven F, Queffeulou E, Pillot M, Dumuis A, Claeysen S, Bockaert J, Pardo L. Conformational toggle switches implicated in basal constitutive and agonist-induced activated states of 5-hydroxytryptamine-4 receptors. Mol Pharmacol 2009; 75: 982-990.
41. Nygaard, R, Frimurer TM, Holst B, Rosenkilde MM, Schwartz TW. Ligand binding and micro-switches in 7TM receptor structures. Trends Pharmacol Sci 2009; 30: 249-259.
42. Gao Z-G, Chen A, Barak D, Kim S-K, Muller CE, Jacobson KA. Identification by site-directed mutagenesis of residues involved in ligand recognition and activation of the human A3 adenosine receptor. J Biol Chem 2002; 277: 19056-19063.
43. Kim S-K, Gao Z-G, Jeong LS, Jacobson KA. Docking studies of agonists and antagonists suggest an activation pathway of the A3 adenosine receptor. J Mol Graph Model 2006; 25: 562-577.
44. Shi L, Liapakis G, Xu R, Guarnieri F, Ballesteros JA, Javitch JA. Beta2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. J Biol Chem 2002; 277: 40989-40996.
45. Jacobson KA, Ji X, Li AH, Melman N, Siddiqui MA, Shin KJ, Marquez VE, Ravi RG. Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists. J Med Chem 2000; 43: 2196-2203.
46. Kim S-K, Gao Z-G, Van Rompaey P, Gross AS, Chen A, Van Calenbergh S, Jacobson KA. Modeling the adenosine receptors: comparison of the binding domains of A2A agonists and antagonists. J Med Chem 2003; 46: 4847-4859.
47. Jeong LS, Choe SA, Gunaga P, Kim HO, Lee HW, Lee SK, Tosh DK, Patel A, Palaniappan KK, Gao ZG, Jacobson KA, Moon HR. Discovery of a new nucleoside template for human A3 adenosine receptor ligands: D-4'-thioadenosine derivatives without 4'-hydroxymethyl group as highly potent and selective antagonists. J Med Chem 2007; 50: 3159-3162.
48. Jacobson KA, Klutz AM, Tosh DK, Ivanov AA, Preti D, Baraldi PG. Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering. Handbook Exp Pharmacol 2009; 193: 123-159.